CXCL9/MIG Antibody (Novimmune patent anti-CXCL9) [mFluor Violet 450 SE]
Novus Biologicals, part of Bio-Techne | Catalog # NBP3-28413MFV450
Recombinant Monoclonal Antibody
Conjugate
Catalog #
Key Product Details
Species Reactivity
Validated:
Human
Applications
ELISA, Flow Cytometry, Functional
Label
mFluor Violet 450 SE (Excitation = 406 nm, Emission = 445 nm)
Antibody Source
Recombinant Monoclonal Human IgG1 Clone # Novimmune patent anti-CXCL9
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Summary
Immunogen
CXCL9
Clonality
Monoclonal
Host
Human
Isotype
IgG1
Applications
Application
Recommended Usage
ELISA
Optimal dilutions of this antibody should be experimentally determined.
Flow Cytometry
Optimal dilutions of this antibody should be experimentally determined.
Functional
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Please Note: Optimal dilutions of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Protein A purified
Formulation
50mM Sodium Borate
Preservative
0.05% Sodium Azide
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark.
Background: CXCL9/MIG
Alternate Names
MIG
Gene Symbol
CXCL9
Additional CXCL9/MIG Products
Product Specific Notices
mFluor(TM) is a trademark of AAT Bioquest, Inc. This conjugate is made on demand. Actual recovery may vary from the stated volume of this product. The volume will be greater than or equal to the unit size stated on the datasheet.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...